دورية أكاديمية
أعرض في EDS

Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study.

التفاصيل البيبلوغرافية
العنوان: Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study.
المؤلفون: Ansell SM; Mayo Clinic, Rochester, MN., Bröckelmann PJ; University of Cologne, Cologne, Germany and Center for Integrated Oncology Aachen Bonn Duesseldorf, Bonn, Germany., von Keudell G; Memorial Sloan Kettering Cancer Center, New York, NY., Lee HJ; University of Texas MD Anderson Cancer Center, Houston, TX., Santoro A; Humanitas University, Pieve Emanuele, Milan, Italy and IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Rozzano, Milan, Italy., Zinzani PL; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Instituto di Ematologia 'Seràgnoli' and Università di Bologna, Bologna, Italy., Collins GP; Churchill Hospital, Oxford, United Kingdom., Cohen JB; Winship Cancer Institute, Atlanta, GA., de Boer JP; Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Kuruvilla J; Princess Margaret Cancer Centre, Toronto, ON, Canada., Savage KJ; BC Cancer, Vancouver, BC, Canada., Trněný M; Charles University in Prague, Prague, Czech Republic., Provencio M; University Hospital Puerta de Hierro, Majadahonda, Spain., Jäger U; Medical University of Vienna, Vienna, Austria., Willenbacher W; Innsbruck Medical University and Sydena GmbH, Connect to Cure, Innsbruck, Austria., Wen R; Bristol Myers Squibb, Princeton, NJ., Akyol A; Bristol Myers Squibb, Princeton, NJ., Mikita-Geoffroy J; Bristol Myers Squibb, Boudry, Switzerland., Shipp MA; Dana-Farber Cancer Institute, Boston, MA., Engert A; University of Cologne, Cologne, Germany and Center for Integrated Oncology Aachen Bonn Duesseldorf, Bonn, Germany., Armand P; Dana-Farber Cancer Institute, Boston, MA.
المصدر: Blood advances [Blood Adv] 2023 Oct 24; Vol. 7 (20), pp. 6266-6274.
نوع المنشور: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Washington, DC : American Society of Hematology, [2016]-
مواضيع طبية MeSH: Hodgkin Disease*/pathology , Immunoconjugates*, Humans ; Nivolumab/therapeutic use ; Neoplasm Recurrence, Local/drug therapy ; Brentuximab Vedotin ; Chronic Disease
مستخلص: Patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) for whom autologous hematopoietic cell transplantation (auto-HCT) had failed experienced frequent and durable responses to nivolumab in the phase 2 CheckMate 205 trial. We present updated results (median follow-up, ∼5 years). Patients with R/R cHL who were brentuximab vedotin (BV)-naive (cohort A), received BV after auto-HCT (cohort B), or received BV before and/or after auto-HCT (cohort C) were administered with nivolumab 3 mg/kg IV every 2 weeks until progression or unacceptable toxicity. Patients in cohort C with complete remission (CR) for 1 year could discontinue nivolumab and resume upon relapse. Among 243 patients (cohort A, n = 63; B, n = 80; and C, n = 100), the objective response rate (ORR) was 71.2% (95% confidence interval [CI], 65.1-76.8); the CR rate was 21.4% (95% CI, 16.4-27.1). Median duration of response, CR, and partial remission were 18.2 (95% CI, 14.7-26.1), 30.3, and 13.5 months, respectively. Median progression-free survival was 15.1 months (95% CI, 11.3-18.5). Median overall survival (OS) was not reached; OS at 5 years was 71.4% (95% CI, 64.8-77.1). In cohort C, all 3 patients who discontinued in CR and were subsequently re-treated achieved objective response. No new or unexpected safety signals were identified. This 5-year follow-up of CheckMate 205 demonstrated favorable OS and confirmed efficacy and safety of nivolumab in R/R cHL after auto-HCT failure. Results suggest patients may discontinue treatment after persistent CR and reinitiate upon progression. This trial was registered at www.clinicaltrials.gov as #NCT02181713.
(© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
References: J Clin Oncol. 2018 May 10;36(14):1428-1439. (PMID: 29584546)
Hematology Am Soc Hematol Educ Program. 2008;:326-33. (PMID: 19074105)
J Clin Oncol. 2013 Feb 1;31(4):456-60. (PMID: 23248254)
J Clin Oncol. 2014 Sep 20;32(27):3059-68. (PMID: 25113753)
JAMA Oncol. 2020 Jun 1;6(6):872-880. (PMID: 32352505)
Cancer Med. 2020 Nov;9(21):7830-7836. (PMID: 32881376)
Br J Haematol. 2009 Jul;146(2):158-63. (PMID: 19438504)
J Clin Oncol. 2012 Jun 20;30(18):2183-9. (PMID: 22454421)
Chin J Cancer Res. 2021 Jun 30;33(3):289-301. (PMID: 34321826)
Nat Immunol. 2001 Mar;2(3):261-8. (PMID: 11224527)
Ann Oncol. 2007 Jun;18(6):1071-9. (PMID: 17426059)
Blood. 2019 Oct 3;134(14):1144-1153. (PMID: 31409671)
N Engl J Med. 2015 Jan 22;372(4):311-9. (PMID: 25482239)
Cancer Immunol Res. 2016 Nov;4(11):910-916. (PMID: 27737878)
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv19-iv29. (PMID: 29796651)
Blood. 2022 Jun 23;139(25):3605-3616. (PMID: 35316328)
Lancet Oncol. 2016 Sep;17(9):1283-94. (PMID: 27451390)
Leuk Lymphoma. 2014 Aug;55(8):1922-4. (PMID: 24138304)
J Exp Med. 2000 Oct 2;192(7):1027-34. (PMID: 11015443)
Leukemia. 2021 Sep;35(9):2672-2683. (PMID: 33658659)
Blood. 2016 Sep 22;128(12):1562-6. (PMID: 27432875)
Int J Hematol. 2020 Nov;112(5):674-689. (PMID: 32748216)
J Clin Oncol. 2021 Oct 1;39(28):3109-3117. (PMID: 34170745)
Blood Adv. 2020 Jun 23;4(12):2617-2622. (PMID: 32556281)
Ther Adv Hematol. 2021 Aug 19;12:20406207211038181. (PMID: 34434538)
J Clin Oncol. 2023 Feb 20;41(6):1193-1199. (PMID: 36508302)
Br J Haematol. 2022 Jul;198(1):82-92. (PMID: 35468225)
Blood. 2021 Mar 11;137(10):1318-1326. (PMID: 32992341)
Lancet Oncol. 2021 Apr;22(4):512-524. (PMID: 33721562)
معلومات مُعتمدة: P30 CA008748 United States CA NCI NIH HHS
سلسلة جزيئية: ClinicalTrials.gov NCT02181713
المشرفين على المادة: 31YO63LBSN (Nivolumab)
7XL5ISS668 (Brentuximab Vedotin)
0 (Immunoconjugates)
تواريخ الأحداث: Date Created: 20230802 Date Completed: 20240108 Latest Revision: 20240110
رمز التحديث: 20240110
مُعرف محوري في PubMed: PMC10589773
DOI: 10.1182/bloodadvances.2023010334
PMID: 37530622
قاعدة البيانات: MEDLINE
الوصف
تدمد:2473-9537
DOI:10.1182/bloodadvances.2023010334